Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Controlled Clinical Study of Endostar/PD-1 Inhibitors Combined With PP as First-line Treatment for Advanced Non-squamous Cell Lung Cancer With Negative Driving Gene

NCT04063449 is registered in ClinicalTrials.gov with Dong Wang as lead sponsor.

NCT NCT04063449
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04063449 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Controlled Clinical Study of Endostar/PD-1 Inhibitors Combined With PP as First-line Treatment for Advanced Non-squamous Cell Lung Cancer With Negative Driving Gene
Lead sponsor
Dong Wang
Phase
Not applicable
Overall status
Unknown status
Start date
August 20, 2019
Completion date
June 30, 2021
Enrollment
170 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-squamous non-small cell lung cancer